评估一个三机构癌症研究能力建设计划,用于早期阶段的研究人员
Kathryn S Maxwell1, Lecarde Webb2, Desiree Rivers3
1University of Alabama at Birmingham, Birmingham, AL, UK. ksmaxwell@uabmc.edu.
概括
全方位伙伴关系促进癌症健康公平 (CPACHE) 计划成功培养了早期研究人员 (ESI) 和博士后研究员. 结构化培训和指导显著促进了癌症研究职业,特别是在资源不足的机构.
科学领域:
- 癌症 卫生 公平 研究 研究
- 调查员培训和发展研究员培训和发展
- 瘤学中的健康差异
背景情况:
- 国家癌症研究所 (NCI) 的全面伙伴关系促进癌症健康公平 (CPACHE) 倡议促进资源不足的机构和NCI指定的癌症中心之间的合作.
- 长期的合作伙伴关系旨在增强癌症研究能力和劳动力发展.
- 摩尔豪斯医学院/图斯基基大学/阿拉巴马大学伯明翰奥尼尔综合癌症中心合作伙伴关系是CPACHE的一个关键项目,专注于调查员培训.
研究的目的:
- 评估为期一年的研究教育计划对早期研究人员 (ESI) 和博士后的纵向影响.
- 评估该计划在建立癌症研究技能,增强指导和支持职业发展方面的有效性.
- 为缺乏资源的机构的调查人员提供优化类似培训计划的见解.
主要方法:
- 来自研究教育核心的行政记录的分析,用于学者和导师.
- 使用Scopus和PubMed数据库来跟踪出版物.
- 雇佣NIH RePORTER数据库以确定获得赠款资金的情况.
主要成果:
- 89名项目学者中,近95%的人至少获得了一本出版物.
- 70%的学者有第一作者发表的论文,62%有高级作者发表的论文.
- 大约20%的学者获得了NIH资金作为主要研究员.
结论:
- 三机构培训计划有效地吸引和支持致力于癌症研究的研究人员.
- 结构化的培训,密集的指导和跨机构的合作大大有助于学术职业发展.
- 调查结果为加强研究员培养计划提供了宝贵的见解,特别是对于缺乏资源的机构的ESI和博士后研究员.
相关概念视频
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
01:28Preclinical Development: Overview
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...